DUBLIN, Dec. 23, 2021 /PRNewswire/ Endo International plc (NASDAQ: ENDP) announced today that its subsidiary Endo Ventures Limited has entered into definitive agreements with SK Biopharmaceuticals
OTTAWA (dpa-AFX) - Canadian specialty pharmaceutical company Paladin Labs Inc., a unit of Endo International plc (ENDP), announced Wednesday Health Canada's approval of Wakix (pitolisant).The drug
Radius Health Announces Commercial Agreement with Paladin Labs for Abaloparatide in Canada
Agreement incorporates TYMLOS
® and abaloparatide-TD
Consideration includes upfront payment, milestones based on clinical, regulatory and commercial progression, as well as royalties
Key first step in expanding the global footprint for the abaloparatide asset beyond the U.S. and Japan; a key focus area for the company for 2021
BOSTON, Jan. 05, 2021 Radius Health, Inc. (“Radius” or the “Company”) (Nasdaq: RDUS) today announced that the Company has entered into definitive agreements with Endo Ventures Limited, a subsidiary of Endo International plc (“Endo”) (NASDAQ: ENDP), to register, commercialize, and distribute abaloparatide on an exclusive basis in Canada. Paladin Labs Inc. (“Paladin”), an operating company of Endo, will be responsible for all commercial activities related to abaloparatide. Under the terms of the agreements, Paladin will pay Radius upfront and mile